���构特征与受体作用机制 — Evidence Review

By Editorial Desk · published 2025-11-29 · last reviewed 2025-12-20 · Topic

If you have been reading about GLP-1 类似物 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-12-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Storage, Handling, and Analytical Verification

Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.

Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.

Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.

Semaglutide at a glance

Mechanism and Pharmacological Class

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Related pages on this site

• Measured briefing
• Robust toolkit
• Optimized trends
• Reliable overview
• Structured casebook
• Scalable reference
• Adaptive reference
• Gradual primer

Molecular Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide Structure and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Reference notes

Studies indicate that a substantial part of the modern vehicle's value comes from intelligent systems, and that these represent most of the current automotive innovation. To facilitate this, the modern automotive engineering process has to handle an increased use of mechatronics. Configuration and performance optimization, system integration, control, component, subsystem and system-level validation of the intelligent systems must become an intrinsic part of the standard vehicle engineering process, just as this is the case for the structural, vibro-acoustic and kinematic design. This requires a vehicle development process that is typically highly simulation-driven.

== Natural occurrence == The half-life of thorium-232 (14 billion years) is more than three times the age of the Earth; thorium-232 therefore occurs in nature as a primordial nuclide. Other thorium isotopes occur in nature in much smaller quantities as intermediate products in the decay chains of uranium-238, uranium-235, and thorium-232. Some minerals that contain thorium include apatite, sphene, zircon, allanite, monazite, pyrochlore, thorite, and xenotime.

=== No development reported === Atomoxetine/orexin antagonist (AD-182) – combination of atomoxetine (norepinephrine reuptake inhibitor) and an orexin receptor antagonist [24] Daridorexant (ACT-541468; nemorexant; Quviviq) – orexin OX1 and OX2 receptor antagonist [25] Lemborexant (Dayvigo; E-2006; LEM) – orexin OX1 and OX2 receptor antagonist [26] Research programme: AMPA receptor agonists - RespireRx (ampakines; CX compounds) – ampakines (AMPA receptor positive allosteric modulators) and brain-derived neurotrophic factor (BDNF) stimulants [27] Research programme: sleep apnoea therapeutics - Apnimed – undefined mechanism of action [28] Seltorexant (JNJ-42847922; JNJ-7922; MIN-202) – orexin OX2 receptor antagonist [29] Vornorexant (ORN-0829; TS-142) – orexin OX1 and OX2 receptor antagonist [30]

Sources: en.wikipedia.org

Notes from published material

== Enzymes that use NADP(H) as a substrate == In 2018 and 2019, the first two reports of enzymes that catalyze the removal of the 2' phosphate of NADP(H) in eukaryotes emerged. First the cytoplasmic protein MESH1 (Q8N4P3), then the mitochondrial protein nocturnin were reported. Of note, the structures and NADPH binding of MESH1 (5VXA) and nocturnin (6NF0) are not related.

In 1940–1941, some 325,000 Polish citizens were deported by the Soviet Union. The number of Polish citizens who died at the hands of the Soviets is estimated at less than 100,000. In 1943–1944, Ukrainian nationalists associated with the Organization of Ukrainian Nationalists (OUN) and the Ukrainian Insurgent Army perpetrated the Massacres of Poles in Volhynia and Eastern Galicia. Estimates of the number of Polish civilian victims vary greatly, from tens to hundreds of thousands. Approximately 90% of Poland's war casualties were the victims of prisons, death camps, raids, executions, the annihilation of ghettos, epidemics, starvation, excessive work and ill treatment. The war left one million children orphaned and 590,000 persons disabled. The country lost 38% of its national assets (whereas Britain lost only 0.8%, and France only 1.5%). Nearly half of pre-war Poland was expropriated by the Soviet Union, including the two great cultural centers of Lwów and Wilno. The policies of Nazi Germany have been judged after the war by the International Military Tribunal at the Nuremberg trials and Polish genocide trials to be aimed at extermination of Jews, Poles and Roma, and to have "all the characteristics of genocide in the biological meaning of this term".

=== Athletics and promotions === Hooters is involved in the sports world. Previous sponsorships include the Miami Hooters, a now defunct Arena Football League team. Hooters formerly sponsored the USAR Hooters Pro Cup, an automobile racing series, and the NGA Pro Golf Tour, a minor league golf tour.

The three substrates of this enzyme are taxusin, oxygen, and a proton. It uses a reduced nicotinamide adenine dinucleotide (NADH) cofactor bound to a heme in cytochrome P450 to give 7β-hydroxytaxusin and water as products. The enzyme is found in the yew tree Taxus cuspidata and is part of the pathway for the biosynthesis of taxol.

Sources: en.wikipedia.org

Further detail

== Properties == Actinides have similar properties to lanthanides. Just as the 4f electron shells are filled in the lanthanides, the 5f electron shells are filled in the actinides. Because the 5f, 6d, 7s, and 7p shells are close in energy, many irregular configurations arise; thus, in gas-phase atoms, just as the first 4f electron only appears in cerium, so the first 5f electron appears even later, in protactinium. However, just as lanthanum is the first element to use the 4f shell in compounds, so actinium is the first element to use the 5f shell in compounds. The f-shells complete their filling together, at ytterbium and nobelium. The first experimental evidence for the filling of the 5f shell in actinides was obtained by McMillan and Abelson in 1940. As in lanthanides (see lanthanide contraction), the ionic radius of actinides monotonically decreases with atomic number (see also actinoid contraction). The shift of electron configurations in the gas phase does not always match the chemical behaviour. For example, the early-transition-metal-like prominence of the highest oxidation state, corresponding to removal of all valence electrons, extends up to uranium even though the 5f shells begin filling before that. On the other hand, electron configurations resembling the lanthanide congeners already begin at plutonium, even though lanthanide-like behaviour does not become dominant until the second half of the series begins at curium.

== Research == Most studies investigating alpha-glucosidase and alpha-amylase inhibitory activity use acarbose as reference. In human T2DM patients, acarbose reduces total triglyceride levels. Acarbose has a similar effect in non-T2DM patients with isolated familial hypertriglyceridemia. In smaller samples of healthy human volunteers, acarbose increases postprandial GLP-1 levels. In studies conducted by three independent laboratories by the US National Institute on Aging's intervention testing programme, acarbose was shown to extend the lifespan of female mice by 5% and of male mice by 22%. A pooled analysis of data from 10 observational studies show that acarbose appears to reduce body weight irrespective of glycemic control in diabetic patients. The effect is more pronounced in patients of the female sex, South East Asian and East Asian ethnicity, younger age, higher body mass index, short duration of diabetes, or no previous treatment.

Russia expert Leon Aron said: "The next target of opportunity is Ukraine – not the entire country, but the Crimean peninsula and Sebastopol, which is home to the Black Sea fleet." The Times wrote on 17 August 2008, "The US intelligence services had been warning that the Russians were preparing for war, but it did not occur to them that fighting would break out just as the world was settling down to watch the Beijing Olympics." Los Angeles Times wrote on 17 August 2008, "A trove of evidence strongly suggests that Russia was preparing the logistics for war well before Aug. 7." Russia began anti-Georgian campaign as early as 2005 and the newspaper noted that Russia began preparing for the war after Georgia submitted a bid to NATO in April 2008 which was "a decisive factor in the decision to escalate the conflict." On 25 August 2008, journalist Matthew Continetti argued that "Whatever the precise sequence of events, however, nothing Saakashvili did provided a reason for Putin to invade Georgia proper; or to bomb Georgian targets in the days after the initial ceasefire; or to charge Saakashvili with crimes against humanity; or to attempt regime change in a democracy that abides by international norms". Continetti also denied the claim that the ultimate blame for the war laid with the United States, NATO and EU.

Sources: en.wikipedia.org

Frequently asked questions